BECAFRI Trademark

Trademark Overview


On Wednesday, November 8, 2017, a trademark application was filed for BECAFRI with the United States Patent and Trademark Office. The USPTO has given the BECAFRI trademark a serial number of 87677145. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 14, 2022. This trademark is owned by Allergan Pharmaceuticals International Limited. The BECAFRI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lo...
becafri

General Information


Serial Number87677145
Word MarkBECAFRI
Filing DateWednesday, November 8, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 14, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 13, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, November 19, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Pharmaceuticals International Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCoolock, Dublin 17
IE

Party NameAllergan Pharmaceuticals International Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCoolock, Dublin 17
IE

Trademark Events


Event DateEvent Description
Monday, February 14, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 14, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 13, 2021SOU EXTENSION 5 GRANTED
Tuesday, July 6, 2021SOU EXTENSION 5 FILED
Tuesday, July 13, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 6, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, January 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 4, 2021SOU EXTENSION 4 GRANTED
Monday, January 4, 2021SOU EXTENSION 4 FILED
Monday, January 4, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, June 16, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 12, 2020SOU EXTENSION 3 GRANTED
Friday, June 12, 2020SOU EXTENSION 3 FILED
Friday, June 12, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, December 24, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 20, 2019SOU EXTENSION 2 GRANTED
Friday, December 20, 2019SOU EXTENSION 2 FILED
Friday, December 20, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, June 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 7, 2019SOU EXTENSION 1 GRANTED
Friday, June 7, 2019SOU EXTENSION 1 FILED
Friday, June 7, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, January 8, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 13, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 13, 2018PUBLISHED FOR OPPOSITION
Wednesday, October 24, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, October 5, 2018LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, October 2, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 31, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 31, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 29, 2018ASSIGNED TO LIE
Monday, August 13, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 27, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 27, 2018NON-FINAL ACTION E-MAILED
Tuesday, February 27, 2018NON-FINAL ACTION WRITTEN
Tuesday, February 20, 2018ASSIGNED TO EXAMINER
Sunday, November 19, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 11, 2017NEW APPLICATION ENTERED